UCSF Helen Diller Family
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Koshkin, Vadim
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
TAS-120-203, NCT04601857 / 2020-000945-15: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
43
Europe, US
futibatinib and pembrolizumab (KEYTRUDA®)), TAS120 and MK-3475-B04
Taiho Oncology, Inc., Merck Sharp & Dohme LLC
Advanced and Metastatic Urothelial Cancer
03/24
08/25
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
11/26
05/28
NCT06470282: Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Not yet recruiting
1/2
47
US
Enfortumab Vedotin, Padcev, Pembrolizumab, Keytruda, Intensity Modulated Radiation Therapy (IMRT), Standard of care IMRT, Transurethral Resection of Bladder Tumor, Transurethral resection (TURBT), Cystoscopy (CS), CS, Computed Tomography (CT), CT Scan, Magnetic Resonance Imaging (MRI), MRI Scan, Positron Emission Tomography (PET), PET Scan
University of California, San Francisco, Astellas Pharma Inc, Merck Sharp & Dohme LLC
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
11/27
11/27
UPLIFT, NCT05113537: Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Recruiting
1/2
30
US
Abemaciclib, Abemaciclib Oral, LY-2835219, Verzenio, Lutetium Lu 177-PSMA-617, 177Lu-labeled PSMA-617, Lutetium Lu 177 Vipivotide Tetraxetan
Vadim S Koshkin, Prostate Cancer Foundation, Eli Lilly and Company
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
12/25
07/27
NCT05902494: HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Recruiting
N/A
350
Europe, US
Seagen Inc.
Urothelial Carcinoma
09/25
09/25

Download Options